Published on 21/12/2025
How to Register a Clinical Trial on ClinicalTrials.gov: A Complete Step-by-Step Guide
Introduction to ClinicalTrials.gov and Registration Mandates
ClinicalTrials.gov is a publicly accessible database managed by the U.S. National Library of Medicine and mandated by FDAAA 801, 42 CFR Part 11, and the ICMJE. Sponsors, investigators, and responsible parties are required to register trials to promote transparency, enable ethical oversight, and meet legal disclosure requirements. Failure to register or disclose results can lead to noncompliance notices, financial penalties, and publication restrictions.
All applicable clinical trials (ACTs), including Phase II–IV interventional studies, must be registered within 21 days of enrolling the first participant. This guide walks you through each step of registering your study correctly in the PRS (Protocol Registration and Results System) interface. For detailed FDA policy context, visit the FDA official guidance page.
Step 1: Obtaining a PRS Account and Login Credentials
The first step in registering a clinical trial is creating a PRS account. Institutions usually assign a PRS Administrator who manages user roles. You must request a new account by emailing register@clinicaltrials.gov with the following:
- Name of the responsible party or sponsor
- Official organization name
- Contact email and phone number
Once your organization
Step 2: Creating a New Study Record
After logging in, click “Create” under the Study Records menu. You’ll be prompted to complete the following required sections:
- Study Title and Brief Summary – Must align with protocol header
- Study Type – Interventional, observational, or expanded access
- Study Design – Allocation, masking, intervention model, etc.
- Conditions – Enter MeSH terms if available
- Interventions – Drug, procedure, or device involved
Each field is guided by detailed help text. Use standardized terms where possible. For example, “Randomized, Double-Blind, Placebo-Controlled” are valid intervention model terms accepted by FDA reviewers.
Step 3: Entering Outcome Measures and Timepoints
Primary and secondary outcome measures are critical for registry accuracy. You must specify:
- Measure Title: e.g., “Change in HbA1c levels from baseline to 12 weeks”
- Time Frame: e.g., “Baseline, Week 12”
- Description: How the measure is assessed
Outcome data should be measurable, time-bound, and clearly tied to your study endpoints. This ensures consistency between registered data and later Clinical Study Reports (CSRs). Use numerical units when possible, like “mmHg,” “ng/mL,” or “mg/dL.”
Step 4: Location, Site Contact, and Oversight Details
Next, you’ll enter the study location, principal investigator details, and regulatory oversight fields. Ensure:
- Facility name, address, and contact phone/email are accurate for each participating site
- IRB status is correctly identified as approved, pending, or exempt
- FDA-regulated product flag is set to “Yes” for drugs/devices
- IND/IDE status is declared if applicable
Many registrations get rejected due to incomplete contact details or outdated IRB statuses. Verify with your institutional review board coordinator before finalizing. All location and contact fields are mandatory for trials recruiting in the U.S. or abroad.
Step 5: Uploading the Study Protocol and Documents
While not required for initial registration, uploading the full study protocol and statistical analysis plan (SAP) is encouraged for transparency. Documents must be de-identified and in PDF format with digital signatures removed. Use file naming conventions like:
- StudyProtocol_V1_2025.pdf
- SAP_V1.0_Appendix.pdf
These documents are housed under “Documents” in the PRS menu and are publicly visible once posted. Some journals now require protocol uploads as a condition of manuscript submission, so uploading early improves compliance.
Step 6: Record Verification and Quality Control Review
Before submission, use the “Preview” and “Validate” tools within PRS. Common errors include:
- Missing or inconsistent dates (e.g., Enrollment Start before IRB Approval)
- Inappropriate time frames (e.g., follow-up of 52 weeks but outcome reported at 24 weeks only)
- Generic titles like “study drug” instead of brand/generic name
Once validation is error-free, submit the record for PRS Quality Control (QC) review. The QC team usually returns feedback within 3–5 business days. All comments must be addressed before the record can go live on ClinicalTrials.gov.
Conclusion
Registering a trial on ClinicalTrials.gov is a critical part of regulatory compliance, ethical transparency, and public communication. By following each step carefully—account creation, data entry, outcome measures, and QC feedback—you can ensure your trial is correctly and promptly registered. Regulatory authorities increasingly scrutinize registration accuracy and timelines, so early and accurate submissions reduce downstream risks.
To explore additional regulatory compliance resources, visit PharmaValidation.in or access training material at ICH.org.